Cargando…

Effect of Ambroxol chaperone therapy on Glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease

Type 3 Gaucher disease (GD3) is characterized by progressive neurological features in addition to the typical systemic manifestations. Enzyme replacement therapy (ERT), the main stay treatment for Gaucher disease (GD), is not efficacious for the neurological manifestations. Ambroxol, in combination...

Descripción completa

Detalles Bibliográficos
Autores principales:	Charkhand, Behshad, Scantlebury, Morris H., Narita, Aya, Zimran, Ari, Al-Hertani, Walla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713848/ https://www.ncbi.nlm.nih.gov/pubmed/31467847 http://dx.doi.org/10.1016/j.ymgmr.2019.100476

Ejemplares similares

Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease
por: Dinur, Tama, et al.
Publicado: (2023)

Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review
por: Revel-Vilk, Shoshana, et al.
Publicado: (2020)

Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease
por: Hurvitz, Noa, et al.
Publicado: (2019)

Glucosylsphingosine (Lyso-Gb(1)): An Informative Biomarker in the Clinical Monitoring of Patients with Gaucher Disease
por: Gayed, Matthew M., et al.
Publicado: (2022)

Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review
por: Giuffrida, Gaetano, et al.
Publicado: (2023)

Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic Formulations
por: Dinur, Tama, et al.
Publicado: (2021)

An observational study to investigate the relationship between plasma glucosylsphingosine (lyso-Gb1) concentration and treatment outcomes of patients with Gaucher disease in Japan
por: Ida, Hiroyuki, et al.
Publicado: (2022)

Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?
por: Dinur, Tama, et al.
Publicado: (2022)

Insights into the Value of Lyso-Gb1 as a Predictive Biomarker in Treatment-Naïve Patients with Gaucher Disease Type 1 in the LYSO-PROOF Study
por: Curado, Filipa, et al.
Publicado: (2023)

Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study
por: Narita, Aya, et al.
Publicado: (2016)

Use of Ambroxol as Therapy for Gaucher Disease
por: Zhan, Xia, et al.
Publicado: (2023)

Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease Patients
por: Rolfs, Arndt, et al.
Publicado: (2013)

Treatment Efficiency in Gaucher Patients Can Reliably Be Monitored by Quantification of Lyso-Gb1 Concentrations in Dried Blood Spots
por: Cozma, Claudia, et al.
Publicado: (2020)

High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy
por: Istaiti, Majdolen, et al.
Publicado: (2023)

Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy
por: Kim, Yoon-Myung, et al.
Publicado: (2020)

In vitro and in vivo effects of Ambroxol chaperone therapy in two Italian patients affected by neuronopathic Gaucher disease and epilepsy
por: Ciana, Giovanni, et al.
Publicado: (2020)

Elevated LysoGb3 Concentration in the Neuronopathic Forms of Mucopolysaccharidoses
por: Baydakova, Galina, et al.
Publicado: (2020)

Glucosylsphingosine Causes Hematological and Visceral Changes in Mice—Evidence for a Pathophysiological Role in Gaucher Disease
por: Lukas, Jan, et al.
Publicado: (2017)

The role of glucosylsphingosine as an early indicator of disease progression in early symptomatic type 1 Gaucher disease
por: Stiles, Ashlee R., et al.
Publicado: (2021)

Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase
por: Bendikov-Bar, Inna, et al.
Publicado: (2013)

Lyso-Gb3 modulates the gut microbiota and decreases butyrate production
por: Aguilera-Correa, John-Jairo, et al.
Publicado: (2019)

RIPK3 Contributes to Lyso-Gb3-Induced Podocyte Death
por: Kim, So-Young, et al.
Publicado: (2021)

Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?
por: Duro, Giovanni, et al.
Publicado: (2018)

Review of the safety and efficacy of imiglucerase treatment of Gaucher disease
por: Elstein, Deborah, et al.
Publicado: (2009)

Publisher Correction: Lyso-Gb3 modulates the gut microbiota and decreases butyrate production
por: Aguilera-Correa, John-Jairo, et al.
Publicado: (2020)

Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease
por: Nowak, Albina, et al.
Publicado: (2022)

Elucidating the toxic effect and disease mechanisms associated with Lyso-Gb3 in Fabry disease
por: Nikolaenko, Valeria, et al.
Publicado: (2023)

Dental profile of patients with Gaucher disease
por: Fischman, Stuart L, et al.
Publicado: (2003)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb(3)) in Fabry Transgenic Mice and in the Plasma of Fabry Patients
por: Young-Gqamana, Brandy, et al.
Publicado: (2013)

A Rapid and Simple UHPLC-MS/MS Method for Quantification of Plasma Globotriaosylsphingosine (lyso-Gb3)
por: Perrone, Alessandro, et al.
Publicado: (2021)

Simultaneous Bilateral Femoral Osteonecrosis in Gaucher Disease
por: Cohen, Daniel, et al.
Publicado: (2023)

Elevated glucosylsphingosine in Gaucher disease induced pluripotent stem cell neurons deregulates lysosomal compartment through mammalian target of rapamycin complex 1
por: Srikanth, Manasa P., et al.
Publicado: (2021)

Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey
por: Schwartz, Ida Vanessa D., et al.
Publicado: (2017)

Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2020)

A checklist for managed access programmes for reimbursement co‐designed by Canadian patients and caregivers
por: Young, Andrea, et al.
Publicado: (2018)

Consequences of excessive glucosylsphingosine in glucocerebrosidase-deficient zebrafish.
por: Lelieveld, Lindsey T., et al.
Publicado: (2022)

Simultaneous UV Spectrophotometric Estimation of Ambroxol Hydrochloride and Levocetirizine Dihydrochloride
por: Prabhu, S. Lakshmana, et al.
Publicado: (2008)

Promising Effect of High Dose Ambroxol Treatment on Neurocognition and Motor Development in a Patient With Neuropathic Gaucher Disease 2
por: Aries, Charlotte, et al.
Publicado: (2022)

Correction: Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8ro2f53qi8jl0tfj77aagvf84g